Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Keryx Biopharmaceuticals, a developer of medically important pharmaceutical products for the treatment of cancer and renal disease, has reported net loss of $6.41m for the first quarter ended 31 March 2011, compared to $4.01m for the same period in 2010, representing an increase in net loss of $2.4m.
Subscribe to our email newsletter
Keryx‘s operating loss was $6.48m, compared to $4.1m for the same period in 2010.
Other research and development expenses, for the first quarter ended 31 March 2011, increased by $2.1m, as compared to the first quarter of 2010, principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs.
Keryx CEO Ron Bentsur said during the first quarter, they continued to advance their compounds, perifosine and Zerenex, in Phase 3 development.
"We are focused on meeting the key clinical milestones that we have set out to achieve, while remaining operationally efficient with a well-controlled burn rate," Bentsur said.